Abstract: Disclosed herein are methods of treating or preventing cell death-related sensory cell loss in a subject in need thereof, the method comprising administering an effective amount of one or more neuroprotective peptides to the subject. Also disclosed are methods of treating or preventing drug-induced ototoxicity in a subject in need thereof, the method comprising administering an effective amount of one or more neuroprotective peptides to the subject.

Abstract: This invention provides methods of treating motor disorder side effects associated with the administration of levodopa to a subject having Parkinson's disease, by administering eltoprazine or a pharmaceutically acceptable acid addition salt thereof in doses and dosing schedules which result in beneficial antidyskinetic effects for the subject. In particular, the invention provides methods for reducing dyskinesia associated with Parkinson's disease treatments, and effective doses and dosing regimens of eltoprazine or a pharmaceutically acceptable acid addition salt thereof.

Abstract: Disclosed herein are methods of treating or preventing cell death-related sensory cell loss in a subject in need thereof, the method comprising administering an effective amount of one or more neuroprotective peptides to the subject. Also disclosed are methods of treating or preventing drug-induced ototoxicity in a subject in need thereof, the method comprising administering an effective amount of one or more neuroprotective peptides to the subject.

Abstract: The invention relates to methods for the diagnosis of CTE or the early stages thereof or a predisposition to CTE. The methods are based on quantitative determination of a mitogenically expressible surface markers, and peripherally accessible cells, e.g. skin cells or lymphocytes, (a) prior to and (b) after mitogenic stimulation. A specific stimulation index a:b is an indication of CTE or early stages thereof or of a predisposition to CTE. The invention also relates to kits which are suitable for carrying out the inventive methods of diagnosis.

Abstract: A kinetic energy rotation system is disclosed which comprises a plurality of wind powered generators. A motor rotates the wind powered generators in a horizontal plane and stores kinetic energy due to the rotating mass of the wind powered generators and its support platform. As electricity is generated by the wind powered generators, a portion of the generated electricity is fed back into the motor to maintain the rotation of the wind powered generators. Excess electricity may be redirected to the city's electrical grid, or other local electrical needs.

Abstract: The present invention relates to a class of small molecule hydroxamic acid compounds capable of inhibiting histone deacetylases (HDACs). The present invention also relates to methods of preparation of hydroxamic acid HDAC inhibitor compounds of the invention, which are N-substituted-1,2,3,4-tetrahydroisoquinoline hydroxamic acid derivatives, and their incorporation into pharmaceutical compositions and methods of administration. The present invention also relates to N-substituted-1,2,3,4-tetrahydroisoquinoline hydroxamic acid derivatives, which may be prepared as a hydroxamic acid HDAC inhibitor compound library that can be utilized in screening methods known in the art.

Abstract: The present invention discloses a transgenic fly that expresses the Arctic mutant version of the human A&bgr;42 peptide of human amyloid-&bgr; precursor protein (APP), and a double transgenic fly that expresses both the Tau protein and the human A&bgr;42Arctic peptide of human amyloid-&bgr; precursor protein (APP). The transgenic flies of the present invention provide for models of neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying genetic modifiers, as well as screening methods to identify therapeutic compounds to treat neurodegenerative disorders using the transgenic flies.

Abstract: The present invention discloses a transgenic fly that expresses the Iowa mutant version of the human A&bgr;42 peptide of human amyloid-&bgr; precursor protein (APP), and a double transgenic fly that expresses both the Tau protein and the human A&bgr;42Iowa peptide of human amyloid-&bgr; precursor protein (APP). The transgenic flies of the present invention provide for models of neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying genetic modifiers, as well as screening methods to identify therapeutic compounds to treat neurodegenerative disorders using the transgenic flies.

Abstract: The present invention discloses a transgenic fly that expresses the Dutch mutant version of the human A&bgr;42 peptide of human amyloid-&bgr; precursor protein (APP), and a double transgenic fly that expresses both the Tau protein and the human A&bgr;42Dutch peptide of human amyloid-&bgr; precursor protein (APP). The transgenic flies of the present invention provide for models of neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying genetic modifiers, as well as screening methods to identify therapeutic compounds to treat neurodegenerative disorders using the transgenic flies.

Abstract: The present invention discloses a transgenic fly that expresses the Flemish mutant version of the human A&bgr;42 peptide of human amyloid-&bgr; precursor protein (APP), and a double transgenic fly that expresses both the Tau protein and the human A&bgr;42Flemish peptide of human amyloid-&bgr; precursor protein (APP). The transgenic flies of the present invention provide for models of neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying genetic modifiers, as well as screening methods to identify therapeutic compounds to treat neurodegenerative disorders using the transgenic flies.

Abstract: The present invention relates to a novel D-hydantoinase from Ochrobactrum anthropi that enantio-selectively hydrolyzes D-hydantoins to their corresponding D-N-carbamoyl-amino acids; nucleic acids that encode for the enzyme; expression vectors including the nucleic acids; and host cells capable of expressing the enzyme.

Abstract: The present invention relates to a novel D-hydantoinase from Ochrobactrum anthropi that enantio-selectively hydrolyzes D-hydantoins to their corresponding D-N-carbamoyl-amino acids; nucleic acids that encode for the enzyme; expression vectors including the nucleic acids; and host cells capable of expressing the enzyme.

Abstract: A file system configuration is scored by summing the squares of the sizes of each contiguous section of free space. A set of defragmentation plans, each describing a sequence of file movements, is generated and scored. The defragmentation plan with the highest score is chosen and executed. In moving a file, a temporary file of the same size is created and the file is copied to the temporary file. After the copying, the temporary file is designated as the file, and the file system space originally occupied by the file is unallocated.

Abstract: O-acylated cephalosporins are produced by reacting 3-hydroxymethylcephalosporins with an acyl donor containing at least three carbon atoms and an enzyme which is a Rodosporidium toruloides esterase, a wheat germ lipase, an Aspergillus niger lipase, an orange peel acetylesterase or a Bacillus subtilis esterase. A preferred enzyme is the esterase from Rodosporidium toruloides ATCC 10657. The enzyme can be used while in whole cells or in soluble or inmobilized form.

Abstract: Production of undesired desacetylcephalosporin C during fermentation of cephalosporin C-producing microorganisms is substantially reduced by addition of certain phosphorous compounds to the culture medium.